Fiducial Markers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The fiducial markers market size was valued at USD 180.23 million in 2025 and estimated to grow from USD 190.77 million in 2026 to reach USD 253.36 million by 2031, at a CAGR of 5.85% during the forecast period (2026-2031). This report is Segmented by Product (Metal-Based, Polymer-Based, Liquid/Hydrogel, and More), Modality (CT/CBCT, MRI, Ultrasound, and More), Application (Prostate Cancer, Lung Cancer, and More), End-User (Hospitals, Cancer Specialty Centers, Ambulatory Radiotherapy Clinics, Others), and Geography (North America, Europe, Asia Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Fiducial Markers Market Trends and Insights

Growing Incidence of Cancer

Global cancer diagnoses climbed to more than 20 million in 2023, and epidemiologists project roughly 35 million annual cases by 2050, expanding radiotherapy utilization and, consequently, fiducial marker demand. Half of all cancer patients eventually receive radiation, and tumors such as prostate and lung malignancies, which together dominate fiducial placement, are highly correlated with aging demographics in high-income nations. Asia-Pacific now absorbs a rising portion of this burden, and the region’s capital spending on linear accelerators and particle therapy rooms is accelerating to keep pace. Hospitals in urban China and India increasingly mandate IGRT workflows, positioning the fiducial markers market for sustained long-term growth.

Rising Adoption of Image-Guided Radiotherapy

Cone-beam CT has become a routine adjunct on modern linacs, explaining CT/CBCT’s 57.6% 2024 share of the fiducial markers market. Newer MRI-linac installations deliver superior soft-tissue contrast but require fiducials that do not distort magnetic images; liquid hydrogels, therefore, gain ground at an 8.2% CAGR. The February 2024 FDA clearance for Varian’s HyperSight upgraded CBCT workflow and halved image acquisition time, improving throughput and marker visualization. Even “markerless” tracking research cements the importance of high-contrast reference objects because algorithm training relies on fiducial benchmarks that underpin accuracy ratings.

High Unit Cost of Gold-Based Markers

A single gold marker can cost multiples of polymer alternatives, and patients often need three per lesion, straining budgets in capitated systems. While clinical familiarity upholds gold’s 49.9% share, buyers in Brazil, India, and parts of Eastern Europe now trial polymer or hydrogel substitutes that offer lower acquisition and placement costs without compromising visibility. Hospitals using activity-based costing find that total episodic spend falls when market price declines, particularly once imaging verification and replanning overheads are included.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Reimbursement Coverage for IGRT Procedures
• Emergence of Liquid Hydrogel Fiducials for MRI-Guided Adaptive RT
• Risk of Marker Migration Causing Re-Planning

Segment Analysis

Gold-based devices comprised 49.25% of the fiducial markers market share in 2025, reflecting decades of decision-maker confidence in their radiopacity and inertness. Yet polymer, platinum, and hydrogel formats are steadily chipping away at that dominance as MRI-compatible workflows expand. The fiducial markers market size attributed to liquid hydrogels is rising at a 9.12% CAGR, aided by their artifact-free profile and eventual bio-absorption, a preference shared by clinicians and patients who seek temporary implants.

Clinical trials now demonstrate that polymer markers paired with CBCT achieve equivalent localization accuracy in prostate and lung stereotactic body radiotherapy. Cost differentials, sometimes exceeding 30% per lesion, are relevant in lower-middle-income countries where public insurance must stretch procurement budgets. Premium gold configurations, such as coiled designs that resist migration, retain utility in highly mobile organs, though their unit price limits uptake outside tertiary referral centers.

CT/CBCT systems generated 57.05% of fiducial markers market revenue in 2025 because nearly every linac fleet includes cone-beam hardware, ensuring consistent marker visibility. The fiducial markers market size linked to MRI-guided systems is, however, expanding at an 7.88% CAGR, signaling that soft-tissue contrast superiority is gaining fiscal endorsement among capital-rich centers.

Upgrades such as HyperSight elevate CBCT quality enough to reduce artifacts from metallic markers, prolonging CT relevance. Simultaneously, hybrid MRI-proton prototypes in Europe demonstrate early-stage promise but will need fiducial materials that do not upset magnetic homogeneity or proton range. Ultrasound continues as a placement modality in hepatobiliary lesions, although its real-time tracking role is dwarfed by X-ray or MRI.

Complete Report Scope:

• By Product
  • Metal-based
  • Polymer-based
  • Liquid / Hydrogel Fiducials
  • Bio-absorbable Markers
• By Modality
  • CT / CBCT
  • MRI
  • Ultrasound
  • X-Ray / Fluoroscopy
  • Hybrid MRI-LINAC systems
• By Application
  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Liver and Pancreatic Cancers
  • Others
• By End-User
  • Hospitals
  • Cancer Specialty Centers
  • Ambulatory Radiotherapy Clinics
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the fiducial markers market in 2025, backed by high per-capita health expenditure and clear reimbursement for IGRT procedures. Regulatory certainty under the FDA’s 510(k) process encourages continuous product iteration, while academic centers such as Penn Medicine drive early clinical validation for emerging designs.

Europe follows, supported by structured healthcare financing and the EU MDR framework, which, though demanding, facilitates continent-wide market entry once clearance is earned. Dresden’s MRI-guided proton program showcases European leadership in adaptive technologies reliant on non-metallic fiducials. National authorities, particularly in Germany and the Nordics, reward cost-effective innovations, spurring polymer uptake.

Asia-Pacific is the fastest-growing region, buoyed by national cancer plans in China, Japan, and South Korea that fund proton rooms and high-end MRI-linacs. China’s 77 active proton or heavy-ion projects highlight scale, while local firms develop cost-optimized polymer markers tailored to domestic price points. In Southeast Asia, private hospital chains import hydrogel devices for liver and pancreatic programs catering to medical tourism.

List of Companies Covered in this Report:

• IZI Medical Products
• CIVCO Radiotherapy
• Gold Anchor
• Medtronic
• QLRAD
• Boston Scientific
• Stellar Medical
• QIAGEN
• Nanovi
• Suremark
• Best Medical International
• ViewRay Inc.
• AngioDynamics (Beacon)
• Carbon Medical Technologies
• RaySearch Laboratories
• Standard Imaging
• C. R. Bard (BD)
• Beekley Medical
• Klarity Medical
• Visicoil (ICU Medical)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support